The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share ... only approved medicine that does that is Zepbound, the weight loss therapy marketed ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for ... it will also be adding two new doses, as competition in the space continues to heat ...

Starting July 1, Zepbound will no longer be preferred ... Novo and Lilly have been locked in a fierce competition to dominate the obesity market, which is expected to reach $130 billion by the ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

Regeneron acquired a promising weight management asset that could become lucrative. Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, ...

Lilly and Novo Nordisk NVO presently dominate the market. Mounjaro and Zepbound face strong competition from Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.